Use of PSMA PET/CT imaging before salvage radiotherapy was linked to improved survival for patients with BCR prostate cancer ...
MedPage Today on MSN
Practice-Influencing Results in Oligometastatic Prostate Cancer
Median progression-free survival (PFS) increased from 7.4 months with stereotactic body radiotherapy (SBRT) to 17.6 months with the addition of 177 lutetium (Lu) PNT2002 targeting prostate-specific ...
Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...
News-Medical.Net on MSN
Combining radiopharmaceuticals with targeted radiation improves progression-free survival in prostate cancer patients
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived ...
GE HealthCare strengthens its radiopharmaceutical portfolio by licensing Lantheus' PSMA PET imaging agent, PYLARIFY, for commercialization in Japan.
Across 2025-26, the UBS spodumene price forecasts were cut by between -7-12% and lithium chemical prices by -4-10%, ...
StockStory.org on MSN
Lantheus (LNTH) Stock Trades Up, Here Is Why
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 2.5% in the morning session after it announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback